Related Experiment Video
Updated: Nov 26, 2025
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Gene expression analysis of human prostate cell lines with and without tumor metastasis suppressor CD82
Pushpaja Dodla1, Vanitha Bhoopalan1, Sok Kean Khoo1
1Department of Cell and Molecular Biology, Grand Valley State University, Allendale, MI, 49401, USA.
Background:
Tetraspanin CD82 is a tumor metastasis suppressor that is known to down regulate in various metastatic cancers. However, the exact mechanism by which CD82 prevents cancer metastasis is unclear. This study aims to identify genes that are regulated by CD82 in human prostate cell lines.
Methods:
We used whole human genome microarray to obtain gene expression profiles in a normal prostate epithelial cell line that expressed CD82 (PrEC-31) and a metastatic prostate cell line that does not express CD82 (PC3). Then, siRNA silencing was used to knock down CD82 expression in PrEC-31 while CD82 was re-expressed in PC3 to acquire differentially-expressed genes in the respective cell line.
Results:
Differentially-expressed genes with a P < 0.05 were identified in 3 data sets: PrEC-31 (+CD82) vs PrEC-31(-CD82), PC3-57 (+CD82) vs. PC3-5 V (-CD82), and PC3-29 (+CD82) vs. PC3-5 V (-CD82). Top 25 gene lists did not show overlap within the data sets, except (CALB1) the calcium binding protein calbindin 1 which was significantly up-regulated (2.8 log fold change) in PrEC-31 and PC3-29 cells that expressed CD82. Other most significantly up-regulated genes included serine peptidase inhibitor kazal type 1 (SPINK1) and polypeptide N-acetyl galactosaminyl transferase 14 (GALNT14) and most down-regulated genes included C-X-C motif chemokine ligand 14 (CXCL14), urotensin 2 (UTS2D), and fibroblast growth factor 13 (FGF13). Pathways related with cell proliferation and angiogenesis, migration and invasion, cell death, cell cycle, signal transduction, and metabolism were highly enriched in cells that lack CD82 expression. Expression of two mutually inclusive genes in top 100 gene lists of all data sets, runt-related transcription factor (RUNX3) and trefoil factor 3 (TFF3), could be validated with qRT-PCR.
Conclusion:
Identification of genes and pathways regulated by CD82 in this study may provide additional insights into the role that CD82 plays in prostate tumor progression and metastasis, as well as identify potential targets for therapeutic intervention.
Insights
Tetraspanin CD82, a tumor suppressor, regulates genes involved in prostate cancer metastasis. This study identified key genes and pathways affected by CD82, offering potential therapeutic targets for prostate cancer progression.
Area of Science:
- Molecular Biology
- Cancer Research
- Genomics
Background:
- Tetraspanin CD82 functions as a tumor metastasis suppressor.
- CD82 expression is frequently downregulated in metastatic cancers.
- The precise mechanisms of CD82's anti-metastatic role remain largely undefined.
Purpose of the Study:
- To identify genes regulated by CD82 in human prostate cancer cell lines.
- To elucidate the molecular mechanisms underlying CD82's tumor suppressor function in prostate cancer.
Main Methods:
- Whole human genome microarray analysis was performed on prostate cell lines with and without CD82 expression.
- siRNA was used to knockdown CD82 in CD82-expressing cells.
- CD82 was re-expressed in CD82-null cells to identify differentially expressed genes.
Main Results:
- CD82 expression significantly altered the expression of numerous genes, including CALB1, SPINK1, GALNT14, CXCL14, UTS2D, and FGF13.
- Pathways related to cell proliferation, angiogenesis, migration, invasion, cell death, cell cycle, signal transduction, and metabolism were enriched in CD82-deficient cells.
- RUNX3 and TFF3 expression levels were validated using qRT-PCR.
Conclusions:
- The identified genes and pathways regulated by CD82 provide insights into its role in prostate cancer progression.
- This research may lead to the identification of novel therapeutic targets for inhibiting prostate tumor metastasis.
